Type 1 Diabetes Stocks
Advanced therapeutic and medical technology developers in this space focus on replacing insulin dependence through automated glucose monitoring systems, smart pump delivery mechanisms, and regenerative cell therapies.
As of Oct 23, 2026, Type 1 Diabetes has 19 US-listed companies worth $222B combined. The median member moved +1.5% over the past week; BBNX led at +17.2% and BMEA trailed at -30.9%.
Companies in Type 1 Diabetes
- NVO – Novo Nordisk A/S, $172B
- DXCM – DexCom Inc, $29.6B
- PODD – Insulet Corporation, $10.3B
- MMED – MiniMed Group, Inc. Common Stock, $5.2B
- TNDM – Tandem Diabetes Care Inc, $1.1B
- BBNX – Beta Bionics, Inc. Common Stock, $1B
- SANA – Sana Biotechnology Inc, $835M
- LXRX – Lexicon Pharmaceuticals Inc, $783M
- SABS – SAB Biotherapeutics Inc, $262M
- ELDN – Eledon Pharmaceuticals Inc, $190M
- ORMP – Oramed Pharmaceuticals Inc, $171M
- VTVT – vTv Therapeutics Inc, $119M
- BMEA – Biomea Fusion Inc, $50M
- GUTS – Fractyl Health, Inc. Common Stock, $20.6M
- NCEL – NewcelX Ltd., $16.5M
- MODD – Modular Medical Inc, $15.9M
- PMCB – PharmaCyte Biotech Inc, $3.7M
- GNPX – Genprex Inc, $1.7M
- BDRX – Biodexa Pharmaceticals, $860,974